Stay updated on SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page.

Latest updates to the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision label was updated from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe completed clinical trial record is displayed, with details on the semaglutide-versus-sitagliptin study, its design and outcomes, participating locations, results references, and study documents, replacing a 403 error screen.SummaryDifference100%

- Check22 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study details.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH announcement banner was added about the transition from “artificial intelligence” to “Super Intelligence” terminology. The study record remains unavailable behind a 403 error.SummaryDifference1%

- Check36 days agoChange DetectedThe page remains a 403 Forbidden error screen, while its footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page.